- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:46 | Alveus debuts in obesity arena with $160m Series A | ||
| 12:46 | J&J cuts MFN deal with the Trump administration, bolsters US onshoring efforts | ||
| 12:46 | Takeda and Halozyme sign global agreement for Enhanze technology | ||
| 11:46 | Santhera grants Agamree rights to Nxera for DMD | ||
| Do | Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn | ||
| Do | GSK to file for approval of twice-yearly hep B drug on positive Phase III data | ||
| Do | Octapharma receives FDA approval for new Fibryga formulation in AFD | ||
| Do | Day One concludes Mersana Therapeutics acquisition | ||
| Mi | Amgen buys Dark Blue Therapeutics in $840m oncology deal | ||
| Mi | Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus | ||
| Mi | Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis | ||
| Mi | Zai Lab's Augtyro receives NMPA approval for solid tumours in China | ||
| Di | CDC shrinks childhood vaccine recommendation list to mirror "peer nations" | ||
| Di | Takeda and Protagonist seek FDA approval for rusfertide to treat PV | ||
| Di | Aktis Oncology kicks 2026 IPO cycle off with $210m target | ||
| Di | Arrowhead receives Health Canada authorisation for Redemplo to treat FCS | ||
| Mo | Sanofi and Earendil Labs forge $2.56bn autoimmune deal | ||
| Mo | Insilico and Servier announce $888m oncology research agreement | ||
| Mo | Biogen's Tysabri to be used on England's NHS for highly active MS | ||
| Mo | Samsung Bioepis initiates Byooviz commercialisation in Europe | ||
| 02.01. | Valneva takes back charge of chikungunya vaccine supply in Asia | ||
| 02.01. | Outlook Therapeutics receives FDA response on ONS-5010 for wet AMD | ||
| 31.12.25 | FDA approves Vanda Pharmaceuticals' motion sickness drug Nereus | ||
| 31.12.25 | Emmaus, NIT sign Endari distribution agreement | ||
| 30.12.25 | Genmab shelves Phase III lung cancer candidate |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .